FASTinov patented methodology is based on an early detection of microbial cell lesions or metabolic changes, relying on a proprietary combination of particular fluorescent probes that target specific changes and make these identifiable through flow cytometry. The technology has been optimized such that no flow cytometry knowledge is needed to perform FASTinov AST. Advanced proprietary FASTinov computation then interprets the complex cytometry information and classifies bacterial cells in terms of their susceptibility phenotype in a growth independent manner.